These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 29844119)

  • 1. Notch-Induced Myeloid Reprogramming in Spontaneous Pancreatic Ductal Adenocarcinoma by Dual Genetic Targeting.
    Cheung PF; Neff F; Neander C; Bazarna A; Savvatakis K; Liffers ST; Althoff K; Lee CL; Moding EJ; Kirsch DG; Saur D; Bazhin AV; Trajkovic-Arsic M; Heikenwalder MF; Siveke JT
    Cancer Res; 2018 Sep; 78(17):4997-5010. PubMed ID: 29844119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
    Zhang S; Chung WC; Xu K
    Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcription factor NFAT5 contributes to the glycolytic phenotype rewiring and pancreatic cancer progression via transcription of PGK1.
    Jiang Y; He R; Jiang Y; Liu D; Tao L; Yang M; Lin C; Shen Y; Fu X; Yang J; Li J; Huo Y; Hua R; Liu W; Zhang J; Shen B; Zhang Z; Sun Y
    Cell Death Dis; 2019 Dec; 10(12):948. PubMed ID: 31827081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desmoplasia and oncogene driven acinar-to-ductal metaplasia are concurrent events during acinar cell-derived pancreatic cancer initiation in young adult mice.
    Johnson BL; d'Alincourt Salazar M; Mackenzie-Dyck S; D'Apuzzo M; Shih HP; Manuel ER; Diamond DJ
    PLoS One; 2019; 14(9):e0221810. PubMed ID: 31490946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival of pancreatic ductal adenocarcinoma is doubled by
    Lee JS; Lee H; Woo SM; Jang H; Jeon Y; Kim HY; Song J; Lee WJ; Hong EK; Park SJ; Han SS; Kim SY
    Theranostics; 2021; 11(7):3472-3488. PubMed ID: 33537098
    [No Abstract]   [Full Text] [Related]  

  • 6. Generation of a pancreatic cancer model using a Pdx1-Flp recombinase knock-in allele.
    Wu J; Liu X; Nayak SG; Pitarresi JR; Cuitiño MC; Yu L; Hildreth BE; Thies KA; Schilling DJ; Fernandez SA; Leone G; Ostrowski MC
    PLoS One; 2017; 12(9):e0184984. PubMed ID: 28934293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
    Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
    J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice.
    Liao J; Chung YT; Yang AL; Zhang M; Li H; Zhang W; Yan L; Yang GY
    Mol Carcinog; 2013 Sep; 52(9):739-50. PubMed ID: 22549877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Notch signaling pathway in pancreatic tumorigenesis.
    Chung WC; Xu K
    Adv Cancer Res; 2023; 159():1-36. PubMed ID: 37268393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells.
    Pickup MW; Owens P; Gorska AE; Chytil A; Ye F; Shi C; Weaver VM; Kalluri R; Moses HL; Novitskiy SV
    Cancer Immunol Res; 2017 Sep; 5(9):718-729. PubMed ID: 28775207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathways.
    Wang Z; Banerjee S; Ahmad A; Li Y; Azmi AS; Gunn JR; Kong D; Bao B; Ali S; Gao J; Mohammad RM; Miele L; Korc M; Sarkar FH
    PLoS One; 2011; 6(6):e20537. PubMed ID: 21673986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioinformatics and Functional Analyses Implicate Potential Roles for EOGT and L-fringe in Pancreatic Cancers.
    Barua R; Mizuno K; Tashima Y; Ogawa M; Takeuchi H; Taguchi A; Okajima T
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33562410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Deletion of Galectin-3 Inhibits Pancreatic Cancer Progression and Enhances the Efficacy of Immunotherapy.
    Yang D; Sun X; Moniruzzaman R; Wang H; Citu C; Zhao Z; Wistuba II; Wang H; Maitra A; Chen Y
    Gastroenterology; 2024 Jul; 167(2):298-314. PubMed ID: 38467382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS
    Principe DR; Overgaard NH; Park AJ; Diaz AM; Torres C; McKinney R; Dorman MJ; Castellanos K; Schwind R; Dawson DW; Rana A; Maker A; Munshi HG; Rund LA; Grippo PJ; Schook LB
    Sci Rep; 2018 Aug; 8(1):12548. PubMed ID: 30135483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.
    Hosein AN; Dangol G; Okumura T; Roszik J; Rajapakshe K; Siemann M; Zaid M; Ghosh B; Monberg M; Guerrero PA; Singhi A; Haymaker CL; Clevers H; Abou-Elkacem L; Woermann SM; Maitra A
    Gastroenterology; 2022 Apr; 162(4):1303-1318.e18. PubMed ID: 34973294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma.
    Mazur PK; Einwächter H; Lee M; Sipos B; Nakhai H; Rad R; Zimber-Strobl U; Strobl LJ; Radtke F; Klöppel G; Schmid RM; Siveke JT
    Proc Natl Acad Sci U S A; 2010 Jul; 107(30):13438-43. PubMed ID: 20624967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose metabolism during tumorigenesis in the genetic mouse model of pancreatic cancer.
    Pasquale V; Dugnani E; Liberati D; Marra P; Citro A; Canu T; Policardi M; Valla L; Esposito A; Piemonti L
    Acta Diabetol; 2019 Sep; 56(9):1013-1022. PubMed ID: 30989379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma.
    Than MT; O'Hara M; Stanger BZ; Reiss KA
    Mol Cancer Ther; 2024 Oct; 23(10):1378-1388. PubMed ID: 39118358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.